- NHS data shows that the percentage of children getting their first dose of the measles, mumps and rubella vaccine (MMR) by their fifth birthday has reached 95% for the first time.
- A study by leading health academics has revealed that more British women than ever are accessing abortion pills in the UK. Recent data from the Medicines and Healthcare products Regulatory Agency (MHRA) showed that the number of abortion pills seized in Britain has increased dramatically in recent years, from just 5 pills in 2013 to 375 in 2016.
- Sales of a sterilisation device are being halted in all countries bar the US, weeks after the Victoria Derbyshire show reported it could cause problems. The Essure implant, which is available on the NHS, has left some women in chronic pain, and some have even needed hysterectomies to remove it.
News on Health Professional Radio. Today is the 23rd of September 2017. Read by Tabetha Moreto. Health News
National Health Service data shows that the percentage of children getting their first dose of the measles, mumps and rubella (MMR) vaccine by their fifth birthday has reached ninety five percent for the first time. This meets a World Health Organization target. Coverage has been increasing in England for the past ten years. The NHS says children should have two doses of the vaccine before starting school. But only eighty seven point six percent had received both doses by their fifth birthday. The MMR vaccine is given on the NHS as a single injection to babies as part of their routine vaccination schedule, usually within a month of their first birthday.
They should then have a second injection of the vaccine before starting school, usually at three years and four months. Figures published by NHS Digital show that coverage of the first MMR vaccine by the age of five was eighty five point nine percent in two thousand six and two thousand seven, rising every year to ninety five percent in two thousand sixteen and two thousand seventeen. However, the percentage of children being vaccinated with the first dose by their second birthday has gone down for the third year in a row, to ninety one point six percent. MMR vaccination rates dipped after a panic caused by discredited former doctor Andrew Wakefield, who falsely claimed in the late nineteen nineties that the jab caused autism.
Doctor Mary Ramsay, head of immunisations at Public Health England, said: “England is considered to be a world leader in childhood vaccination, with one of the most comprehensive programmes in the world.
A study by leading health academics has revealed that more British women than ever are accessing abortion pills in the UK. In the four month research period, academics writing for the sexual health journal Contraception found that five hundred nineteen women attempted to access the pills in Britain, even in areas where abortion is lawful and funded. In a bid to access the pills, the British women contacted Woman on Web, a self-described digital community of women who have had abortions, medical doctors, researchers, and individuals and organizations that support abortion rights. And although the site has a global focus when it comes to providing abortion pills, it still received hundreds of requests from within the United Kingdom. Recent data from the Medicines and Healthcare products Regulatory Agency (MHRA) showed that the number of abortion pills seized in Britain has increased dramatically in recent years, from just five pills in two thousand thirteen to three hundred seventy five in two thousand sixteen.
Clare Murphy, director of External Affairs at the British Pregnancy Advisory Service said:
“The numbers of women in Britain seeking abortion pills online documented in this study are quite staggering, particularly given that it covers just one service over a four month period.”
And under laws which date back to eighteen sixty one, any woman who uses these pills to induce a miscarriage can be sentenced to life in prison. The BPA director added: “We prepare to mark the fiftieth anniversary of the nineteen sixty seven Abortion Act next month, it’s high time to create a framework that meets the needs of women today, respects their ability to make their own decisions about their own pregnancies, and provides them with accessible high-quality healthcare services to exercise that choice.”
Sales of a sterilisation device are being halted in all countries bar the US, weeks after the Victoria Derbyshire show reported it could cause problems. The Essure implant, which is available on the NHS, has left some women in chronic pain, and some have even needed hysterectomies to remove it. The pharmaceutical company Bayer said the decision to stop sales was being taken for commercial reasons. The sale of the implants in the EU was temporarily suspended last month. Bayer has asked hospitals in the UK not to use their existing stocks during this time. It is a voluntary request and up to individual trusts to decide what to do.
The small coil implants, which are made of nickel and polyester (PET) fibres, are used as a sterilisation device to stop eggs reaching the womb. They are inserted into the fallopian tubes where they are designed to trigger inflammation, causing scar tissue to build up and eventually block the tubes, known as a hysteroscopic sterilisation. They can cause intense pain, and some women are thought to react badly to the nickel and plastic. Because of the way the coils attach to the fallopian tubes, the only way to take them out is to remove a woman’s fallopian tubes and often her uterus. In other cases the device has been found to perforate a fallopian tube and fallen out, embedding itself elsewhere in the body.
A spokeswoman for the FDA said it was aware Bayer was no longer marketing Essure outside the US and the company had confirmed it was committed to continuing the testing as ordered.
A statement from Bayer said: “We would like to reassure all patients, especially those with Essure, as well as health professionals, that this decision has been taken for commercial reasons and is not linked to any problems with safety or with the quality of the product.